

**Amendments to the Claims**

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1-14. (Canceled)

15. (Original) A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising nitrosated or nitrated hemoglobin in a therapeutically effective amount.

16. (Original) The method of Claim 15 wherein the disorder is selected from the group consisting of: myocardial infarction, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, sepsis and unstable angina.

17. (Previously presented) A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising nitrosated hemoglobin in a therapeutically effective amount.

18-58. (Canceled)

59. (Previously presented) A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising nitrosated hemoglobin in a therapeutically effective amount.

60. (Previously presented) A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising nitrosylhemoglobin in a therapeutically effective amount.

61. (Previously presented) The method of Claim 60 wherein the disorder is selected from the group consisting of: myocardial infarction, pulmonary thromboembolism, cerebral thromboembolism, thrombophlebitis, sepsis and unstable angina.
62. (Previously presented) A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising nitrosylhemoglobin in a therapeutically effective amount.
63. (Previously presented) A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising nitrosylhemoglobin in a therapeutically effective amount.
64. (Previously presented) A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(III)] in a therapeutically effective amount.
65. (Previously presented) A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(III)] in a therapeutically effective amount.
66. (Previously presented) A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising polynitrosated hemoglobin in a therapeutically effective amount.
67. (Previously presented) A method for treating a disorder resulting from platelet activation or adherence in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(II)] in a therapeutically effective amount.

68. (Previously presented) A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising polynitrosated hemoglobin in a therapeutically effective amount.
69. (Previously presented) A method for preventing thrombus formation in an animal or human, comprising administering to the animal or human a composition comprising SNO-Hb[Fe(II)] in a therapeutically effective amount.
70. (Previously presented) A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising SNO-hemoglobin in a therapeutically effective amount.
71. (Previously presented) A method for inhibiting platelet activation in a mammal, comprising administering to the mammal a composition comprising SNO-methemoglobin in a therapeutically effective amount.